{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T15:20:09Z","timestamp":1776525609067,"version":"3.51.2"},"reference-count":78,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.rceng.2022.02.007","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T17:40:49Z","timestamp":1654623649000},"page":"486-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic and follow-up protocol for adult patients with neurofibromatosis type 1 in a Spanish reference unit"],"prefix":"10.1016","volume":"222","author":[{"given":"I.","family":"Solares","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Vinal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Morales-Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2022.02.007_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-0036-1579766","article-title":"Neurofibromatosis: a review of NF1, NF2, and schwannomatosis","volume":"5","author":"Kresak","year":"2016","journal-title":"J Pediatr Genet"},{"key":"10.1016\/j.rceng.2022.02.007_bib0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.rceng.2022.02.007_bib0015","doi-asserted-by":"crossref","first-page":"100223","DOI":"10.1016\/j.esmoop.2021.100223","article-title":"Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review","volume":"6","author":"Solares","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.rceng.2022.02.007_bib0020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0025","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.3390\/ijms22115850","article-title":"Current understanding of neurofibromatosis type 1, 2, and schwannomatosis","volume":"22","author":"Tamura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rceng.2022.02.007_bib0030","first-page":"575","article-title":"Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference","volume":"45","year":"1988","journal-title":"Arch Neurol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","article-title":"Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus","volume":"62","author":"Viskochil","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.rceng.2022.02.007_bib0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.rceng.2022.02.007_bib0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/374821","article-title":"Elevated risk for MPNST in NF1 microdeletion patients","volume":"72","author":"De Raedt","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.rceng.2022.02.007_bib0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.ejhg.5201676","article-title":"Neurofibromatosis 1","volume":"15","author":"Ferner","year":"2007","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.rceng.2022.02.007_bib0055","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejim.2014.04.004","article-title":"Is it time to change the neurofibromatosis 1 diagnostic criteria?","volume":"25","author":"Tadini","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rceng.2022.02.007_bib0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/dermatopathology8010003","article-title":"Type I neurofibromatosis: case report and review of the literature focused on oral and cutaneous lesions","volume":"8","author":"Buchholzer","year":"2021","journal-title":"Dermatopathology (Basel)"},{"key":"10.1016\/j.rceng.2022.02.007_bib0065","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ajpath.2010.12.056","article-title":"The pathoetiology of neurofibromatosis 1","volume":"178","author":"Jouhilahti","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.rceng.2022.02.007_bib0075","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/088307380201700802","article-title":"Neurofibromatosis 1: clinical manifestations and diagnostic criteria","volume":"17","author":"Friedman","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0080","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajpath.2010.10.041","article-title":"The development of cutaneous neurofibromas","volume":"178","author":"Jouhilahti","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0085","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41416-018-0073-2","article-title":"Cutaneous neurofibromas in the genomics era: current understanding and open questions","volume":"118","author":"Allaway","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rceng.2022.02.007_bib0090","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00431-013-2035-2","article-title":"Ophthalmological assessment of children with neurofibromatosis type 1","volume":"172","author":"Cassiman","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.rceng.2022.02.007_bib0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/01676830600987227","article-title":"Orbitotemporal neurofibromatosis: classification and treatment","volume":"26","author":"Erb","year":"2007","journal-title":"Orbit"},{"key":"10.1016\/j.rceng.2022.02.007_bib0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ana.410410204","article-title":"Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force","volume":"41","author":"Listernick","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00003086-200208000-00013","article-title":"Orthopaedic manifestations of neurofibromatosis in children: an update","author":"Vitale","year":"2002","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.rceng.2022.02.007_bib0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymgme.2007.12.004","article-title":"Generalized metabolic bone disease in neurofibromatosis type I","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.rceng.2022.02.007_bib0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jvs.2007.03.055","article-title":"Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results","volume":"46","author":"Oderich","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.rceng.2022.02.007_bib0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/1096-8628(20001113)95:2<108::AID-AJMG4>3.0.CO;2-0","article-title":"Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1","volume":"95","author":"Lin","year":"2000","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.rceng.2022.02.007_bib0125","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2022.02.007_bib0130","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/ndt\/17.7.1235","article-title":"Management of renal vascular disease in neurofibromatosis type 1 and the role of percutaneous transluminal angioplasty","volume":"17","author":"Booth","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rceng.2022.02.007_bib0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00125817-200205000-00002","article-title":"Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force","volume":"4","author":"Friedman","year":"2002","journal-title":"Genet Med"},{"key":"10.1016\/j.rceng.2022.02.007_bib0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1469-8749.2012.04399.x","article-title":"Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence","volume":"55","author":"Lehtonen","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0145","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","article-title":"The nature and frequency of cognitive deficits in children with neurofibromatosis type 1","volume":"65","author":"Hyman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.rceng.2022.02.007_bib0150","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/WNR.0000000000001275","article-title":"Selective impairment of the executive attentional network in adult patients with neurofibromatosis type 1","volume":"30","author":"Wang","year":"2019","journal-title":"Neuroreport"},{"key":"10.1016\/j.rceng.2022.02.007_bib0155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/08830738030180050501","article-title":"Epilepsy in neurofibromatosis 1","volume":"18","author":"Vivarelli","year":"2003","journal-title":"J Child Neurol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0160","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/epi.12348","article-title":"Epilepsy in individuals with neurofibromatosis type 1","volume":"54","author":"Ostendorf","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.rceng.2022.02.007_bib0165","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/s41436-021-01261-3","article-title":"Increased risk for dementia in neurofibromatosis type 1","volume":"23","author":"Kallionp\u00e4\u00e4","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.rceng.2022.02.007_bib0170","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0175","doi-asserted-by":"crossref","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","article-title":"Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs. in the general population from 1985 to 2020","volume":"4","author":"Landry","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rceng.2022.02.007_bib0180","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ejhg.2011.113","article-title":"Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989","volume":"19","author":"Evans","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.rceng.2022.02.007_bib0185","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rceng.2022.02.007_bib0190","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2022.02.007_bib0195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10880-018-9584-5","article-title":"Lifespan development: symptoms experienced by individuals with neurofibromatosis type 1 associated plexiform neurofibromas from childhood into adulthood","volume":"26","author":"Jensen","year":"2019","journal-title":"J Clin Psychol Med Settings"},{"key":"10.1016\/j.rceng.2022.02.007_bib0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3171\/2012.9.JNS101610","article-title":"Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1","volume":"118","author":"Dunn","year":"2013","journal-title":"J Neurosurg"},{"key":"10.1016\/j.rceng.2022.02.007_bib0205","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":"Neurofibromatosis type 1 revisited","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.rceng.2022.02.007_bib0210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet"},{"key":"10.1016\/j.rceng.2022.02.007_bib0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-006-9266-2","article-title":"Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors","volume":"82","author":"Hagel","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0220","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1212\/01.wnl.0000168830.79997.13","article-title":"Association between benign and malignant peripheral nerve sheath tumors in NF1","volume":"65","author":"Tucker","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.rceng.2022.02.007_bib0225","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.1985.3.4.532","article-title":"Second malignant neoplasms in children: an update from the Late Effects Study Group","volume":"3","author":"Meadows","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0230","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/1097-0142(19830315)51:6<1028::AID-CNCR2820510610>3.0.CO;2-3","article-title":"Postirradiation neurofibrosarcoma","volume":"51","author":"Ducatman","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.rceng.2022.02.007_bib0235","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/1097-0142(19810515)47:10<2503::AID-CNCR2820471033>3.0.CO;2-3","article-title":"Malignant schwannoma\u2014clinical characteristics, survival, and response to therapy","volume":"47","author":"Sordillo","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.rceng.2022.02.007_bib0240","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6","article-title":"Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases","volume":"57","author":"Ducatman","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.rceng.2022.02.007_bib0245","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1212\/01.WNL.0000078813.05925.2C","article-title":"Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment","volume":"61","author":"Baehring","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.rceng.2022.02.007_bib0250","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1212\/WNL.0000000000008092","article-title":"Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1","volume":"93","author":"Ahlawat","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.rceng.2022.02.007_bib0255","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/annonc\/mdq338","article-title":"First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study","volume":"22","author":"Kroep","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0260","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","article-title":"Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits","volume":"159","author":"Nguyen","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.rceng.2022.02.007_bib0265","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00256-019-03290-1","article-title":"Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis","volume":"49","author":"Ahlawat","year":"2020","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0270","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26733","article-title":"Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18 F]FDG-PET imaging. Is it of value in asymptomatic patients?","volume":"65","author":"Azizi","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rceng.2022.02.007_bib0275","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1158\/1078-0432.CCR-17-0589","article-title":"Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1","volume":"23","author":"Evans","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rceng.2022.02.007_bib0280","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.wneu.2017.09.066","article-title":"Clinical value of multiparametric whole-body magnetic resonance imaging over whole-spine magnetic resonance imaging in patients with neurofibromatosis type I","volume":"108","author":"Zhang","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.rceng.2022.02.007_bib0285","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.59.5.759","article-title":"Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1)","volume":"59","author":"Gutmann","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.rceng.2022.02.007_bib0290","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-6420(84)34217-8","article-title":"von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata","volume":"91","author":"Lewis","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.rceng.2022.02.007_bib0295","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3476(89)80137-4","article-title":"Optic gliomas in children with neurofibromatosis type 1","volume":"114","author":"Listernick","year":"1989","journal-title":"J Pediatr"},{"key":"10.1016\/j.rceng.2022.02.007_bib0300","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/neuonc\/noaa036","article-title":"Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference","volume":"22","author":"Packer","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0305","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1212\/WNL.0000000000009458","article-title":"Nonoptic pathway tumors in children with neurofibromatosis type 1","volume":"95","author":"Mahdi","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.rceng.2022.02.007_bib0310","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0315","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.rceng.2022.02.007_bib0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13053-019-0110-z","article-title":"Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature","volume":"17","author":"Suarez-Kelly","year":"2019","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.rceng.2022.02.007_bib0325","first-page":"359","article-title":"Neurofibromatosis and adenocarcinoma of (male) breast","volume":"68","author":"Ronchese","year":"1953","journal-title":"AMA Arch Derm Syphilol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0330","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1897-4287-12-5","article-title":"Neurofibromatosis type I with breast cancer: not only for women!","volume":"12","author":"Lakshmaiah","year":"2014","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.rceng.2022.02.007_bib0335","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BD-140387","article-title":"Neurofibromatosis with male breast cancer\u2014risk factor or co-incidence? Report of two rare cases","volume":"35","author":"Tandon","year":"2015","journal-title":"Breast Dis"},{"key":"10.1016\/j.rceng.2022.02.007_bib0340","doi-asserted-by":"crossref","first-page":"rjw138","DOI":"10.1093\/jscr\/rjw138","article-title":"Neurofibromatosis type 1 and male breast cancer: emerging risk factor?","volume":"2017","author":"Mann","year":"2017","journal-title":"J Surg Case Rep"},{"key":"10.1016\/j.rceng.2022.02.007_bib0345","unstructured":"Comprehensive Cancer Network. Genetic\/familial high-risk assessment: Breast, ovarian, and pancreatic (Version 1.2022). Plymouth Meeting: NCCN; 2021 [Accessed September 2021]. Available on: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."},{"key":"10.1016\/j.rceng.2022.02.007_bib0350","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/eje.0.1500681","article-title":"Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients","volume":"150","author":"Baguet","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0355","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.rceng.2022.02.007_bib0360","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0365","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0370","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/01.pas.0000176433.81079.bd","article-title":"Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases","volume":"30","author":"Miettinen","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0375","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/01.pas.0000159775.77912.15","article-title":"NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics","volume":"29","author":"Andersson","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 4","key":"10.1016\/j.rceng.2022.02.007_bib0380","doi-asserted-by":"crossref","first-page":"iv267","DOI":"10.1093\/annonc\/mdy320","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rceng.2022.02.007_bib0385","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/bjc.1994.431","article-title":"Neurofibromatosis and childhood leukaemia\/lymphoma: a population-based UKCCSG study","volume":"70","author":"Stiller","year":"1994","journal-title":"Br J Cancer"},{"issue":"7 Suppl 1","key":"10.1016\/j.rceng.2022.02.007_bib0390","first-page":"S111","article-title":"Imaging evaluation of plexiform neurofibromas in neurofibromatosis type 1: a survey-based assessment","volume":"97","author":"Ahlawat","year":"2021","journal-title":"Neurology"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S225488742200042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S225488742200042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:49:10Z","timestamp":1762418950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S225488742200042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S225488742200042X"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2022.02.007","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic and follow-up protocol for adult patients with neurofibromatosis type 1 in a Spanish reference unit","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2022.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2022.02.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}